Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 16/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2490242 | 0.97 | GSK3B (0.51) | GSK3BNPC1RAB9ACYP1A2CYP2D6 | |
| SCHEMBL2491787 | 0.95 | GSK3B (0.53) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL2490107 | 0.94 | GSK3B (0.52) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL2488658 | 0.91 | GSK3B (0.57) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL2489227 | 0.90 | GSK3B (0.56) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL3756199 | 0.87 | GSK3B (0.51) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL12207256 | 0.87 | GSK3B (0.51) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL2490008 | 0.87 | GSK3B (0.55) | GSK3BMAP3K12CYP1A2CYP2D6 | |
| SCHEMBL2487613 | 0.85 | GSK3B (0.51) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL2486151 | 0.84 | GSK3B (0.49) | GSK3BGFERCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2057141-B1 | PYRIMIDONE COMPOUNDS AS GSK-3 INHIBITORS | PFIZER PROD INC (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20100292205-A1 | Pyrimidone Compounds As GSK-3 Inhibitors | PFIZER INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292205-A1 | Pyrimidone Compounds As GSK-3 Inhibitors | PFIZER INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292205-A1 | Pyrimidone Compounds As GSK-3 Inhibitors | PFIZER INC. (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2008023239-A1 | PYRIMIDONE COMPOUNDS AS GSK-3 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292205-A1 | Pyrimidone Compounds As GSK-3 Inhibitors | GSK3B, GSK3A, GSKIP | GSK3B 1/4885NPC1 1880/4885RAB9A 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.